Showing results (41-50 of 144) with videos related to
Sort By:
Pageof 15
International Journal of Cancer|April 17, 2016
Managing leptomeningeal melanoma metastases in the era of immune and targeted therapyKeiran S M Smalley, Inna V Fedorenko, Rajappa S Kenchappa, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 25, 2023
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in MelanomaYen-Chou Chen, Muhammad Jaffer, Lylybell Zhou, et al.Scientific Reports|February 19, 2016
BIRC3 is a novel driver of therapeutic resistance in GlioblastomaDapeng Wang, Anders Berglund, Rajappa S Kenchappa, et al.Journal of Visualized Experiments : Jove|April 15, 2024
Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal DiseaseVincent Law, Inna Smalley, Brittany R Evernden, et al.Pigment Cell & Melanoma Research|February 4, 2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesZeynep Eroglu, Sheri L Holmen, Qing Chen, et al.Human Gene Therapy|April 4, 2014
A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancerDaniel Abate-Daga, Kiran H Lagisetty, Eric Tran, et al.Pigment Cell & Melanoma Research|April 20, 2026
A New Era in Leptomeningeal Disease (LMD): Recent Advancements in Immunocellular and Radiation Therapies in Melanoma LMD, What Has Been Done and Future DirectionsPratiksha Patra, Maria Jacome, Kamran A Ahmed, et al.Current Oncology Reports|January 21, 2022
Advances in Diagnosis and Treatment for Leptomeningeal Disease in MelanomaYolanda Piña, Sirisha Yadugiri, Debra N Yeboa, et al.Cancer Control : Journal of the Moffitt Cancer Center|October 8, 2021
Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With <i>BRAF</i> V600E-Mutated GliomasMichael J Fusco, Yolanda Piña, Robert J Macaulay, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|May 24, 2007
Proteolytic disassembly is a critical determinant for reovirus oncolysisTommy Alain, Tom Sy Kim, Xueqing Lun, et al.Pageof 15